Diabetes Drug Recall 2020: New Metformin Warning Issued Over Cancer Concerns

Metformin was previously uncovered to possibly contain high levels of a cancer-causing ingredient, resulting in a string of recalls for the diabetes drug. Nostrum Laboratories is now recalling even more Metformin medication because it was also found to contain nitrosamine impurities above the limits found acceptable by the U.S. Food and Drug Administration (FDA).

Metformin is used for blood glucose management for adults with Type 2 diabetes. The latest recall stems from high levels of N-Nitrosodimethylamine (NDMA) that are above the limits set by the FDA. NDMA has also been classified as a probable cancer-causing ingredient.

The recall affects four lots of Metformin HCl Extended Release tablets prescribed in 500 and 750 mg dosages and packaged in 100-count bottles. The medication has the NDC numbers 29033-055-01 and 29033-056-01 and the lot numbers MET 100201, MET100401, MET200101, and MET200301. The expiration date on the diabetes drug is May 2022.

The Metformin medication, which is distributed nationwide, can be identified by its off-white, oblong tablets that are debossed with "NM5" or "NM7."

Consumers that have the affected diabetes medication in their possession should obtain a replacement drug or alternative treatment plan. Nostrum Laboratories warns that it could be more dangerous for a patient to stop taking the recalled Metformin drug without first talking to their healthcare provider.

Questions about the recall can be directed to Nostrum Laboratories Medical Affairs at 1-816-308-4941, Monday through Friday from 8 a.m. to 5 p.m. CST or by email at quality@nostrumpharma.com. Medical advice about the medications should be directed to a physician or pharmacist.